



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

4

Complete if Known

Application Number	10/769,144-Conf. #9318
Filing Date	January 30, 2004
First Named Inventor	Tibor KELER
Art Unit	1644
Examiner Name	Not Yet Assigned

Attorney Docket Number CDJ-301

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/Y.K./	A1*	US-4,474,893	10-02-1984	Reading	
	A2*	US-4,946,778	08-07-1990	Ladner et al.	
	A3*	US-4,954,617	09-04-1990	Fanger et al.	
	A4*	US-5,455,030	10-03-1995	Ladner et al.	
	A5*	US-5,476,786	12-19-1995	Huston	
	A6*	US-5,545,807	08-13-1996	Surani et al.	
	A7*	US-5,876,917	03-02-1999	Hart et al.	
	A8*	US-5,922,845	07-13-1999	Deo et al.	
	A9*	US-6,080,409	06-27-2000	Laus et al.	
	A10*	US-6,277,959	08-21-2001	Valladeau et al.	
	A11*	US-6,340,569	01-22-2002	Ball et al.	
	A12*	US-6,432,666	08-13-2002	Hart et al.	
	A13*	US-6,479,247-A1	11-12-2002	Hart et al.	
	A14*	US-20040001853-A1	01-01-2004	George et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/Y.K./	B1	WO-86/01533-A1	03-13-1986	Celltech Limited		
	B2	WO-88/00052-A1	01-14-1988	Trustees of Dartmouth College		
	B3	WO-92/07579-A1	05-14-1992	The Children's Medical Center Corporation		
	B4	WO-92/03918-A1	03-19-1992	Genpharm International, Inc.		
	B5	WO-93/04187-A1	03-04-1993	Medical Research Council		
	B6	WO-93/12227-A1	06-24-1993	Genpharm International, Inc.		
	B7	WO-94/10332-A1	05-11-1994	Medarex, Inc.		
	B8	WO-95/15340-A1	06-08-1995	The Board of Trustees of Leland Stanford Junior University		
	B9	WO-96/23882-A1	08-08-1996	The Rockefeller University		
	B10	WO-97/45449-A1	12-04-1997	Hart, Derek et al.		
	B11	WO-98/24884-A1	06-11-1998	Genpharm International		
	B12	WO-98/15579-A1	04-16-1998	Canterbury Health Limited		
	B13	WO-99/02562-A1	01-21-1999	Schering Corporation		
	B14	WO-99/16455-A1	04-08-1999	The Austin Research Institute		
	B15	WO-99/24554-A2	05-20-1999	University of Pittsburgh		
	B16	WO-99/47673-A2	09-23-1999	Schering Corporation		
	B17	WO-99/55369-A1	11-04-1999	Smithkline Beecham Corporation		
	B18	WO-99/58678-A2	11-18-1999	Micromet GmbH		
	B19	WO-00/00156-A2	01-06-2000	Trustees of Dartmouth College		
	B20	WO-00/00592-A1	01-06-2000	Bae, Yong Soo et al.		
	B21	WO-00/18803-A2	04-06-2000	Schering Corporation		

Examiner
Signature

/Y.K./

Date
Considered

7/16/07


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/769,144-Conf. #9318
(Use as many sheets as necessary)				Filing Date	January 30, 2004
				First Named Inventor	Tibor KELER
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	2	of	4	Attorney Docket Number	CDJ-301

/Y.K./	B22	WO-00/63251-A1	10-26-2000	Katholieke Universiteit Nijmegen		
	B23	WO-01/25492-A1	04-12-2001	Biosite Diagnostics, Inc. et al.		
	B24	WO-03/040169-A2	05-15-2003	Medarex, Inc.		
Y.K./	B25	WO-04/026326-A2	04-01-2004	Stichting Katholieke Universiteit		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/Y.K./	C1	Apostolopoulos, Vasso et al, "Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses," <i>Vaccine</i> , Vol. 18:3174-3184 (2000)				
	C2	Berard, Frederic et al, "Cross-Priming of Naive CD8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells," <i>J. Exp. Med.</i> , Vol. 192(11):1535-1543 (2000)				
	C3	Berlyn, Kathleen A. et al, "Generation of CD4 ⁺ and CD8 ⁺ T Lymphocyte Responses by Dendritic Cells Armed with PSA/Anti-PSA (Antigen/Antibody) Complexes," <i>Clinical Immunology</i> , Vol. 101(3):276-283 (2001)				
	C4	Bird, Robert E. et al, "Single-Chain Antigen-Binding Proteins," <i>Science</i> , Vol. 242(4877):423-426 (1988)				
	C5	Brennan, Maureen et al, "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments," <i>Science</i> , Vol. 229:81-83 (1985)				
	C6	Chien, Nadine C. et al, "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 86:5532-5536 (1989)				
	C7	Frleta, Davor et al, "Class II-targeted antigen is superior to CD40-targeted antigen at stimulating humoral responses <i>in vivo</i> ," <i>International Immunopharmacology</i> , Vol. 1:265-275 (2001)				
	C8	Galfre, G. et al, "Antibodies to major histocompatibility antigens produced by hybrid cell lines," <i>Nature</i> , Vol. 266(7):550-552 (1977)				
	C9	Geissmann, Frédéric et al, "A Subset of Human Dendritic Cells Expresses IgA Fc Receptor (CD89), Which Mediates Internalization and Activation Upon Cross-Linking by IgA Complexes," <i>The Journal of Immunology</i> , Vol. 166:346-352 (2001)				
	C10	Glennie, Martin J. et al, "Preparation and Performance of Bispecific F(ab') ₂ Antibody Containing Thioether-Linked Fab' fragments," <i>The Journal of Immunology</i> , Vol. 139(7):2367-2375 (1987)				
	C11	Hawiger, Daniel et al, "Dendritic Cells Induce Peripheral T Cell Unresponsiveness Under Steady State Conditions <i>In Vivo</i> ," <i>J. Exp. Med.</i> , Vol. 194(6):769-779 (2001)				
Y.K./	C12	He, Li-Zhen et al, "A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor-Associated Antigen, Human Chorionic Gonadotropin β ," <i>Clinical Cancer Research</i> , Vol. 10:1920-1927 (2004)				

Examiner Signature		Date Considered	7/16/07
--------------------	---	-----------------	---------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/769,144-Conf. #9318
				Filing Date	January 30, 2004
				First Named Inventor	Tibor KELER
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	3	of	4	Attorney Docket Number	CDJ-301

/Y.K./	C13	He, Lizhen et al, "An Antigen Presenting Cell-Targeted Cancer Vaccine that Elicits CD4 and CD8 Effector Responses to the hCG β Tumor-Associated Antigen," <i>Proceedings of the American Association for Cancer Research</i> , Vol. 44, 2nd ed., pg. 167 (2003)	
	C14	Karpovsky, Boris et al, "Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fc γ Receptor Antibodies," <i>Journal of Experimental Medicine</i> , Vol. 160:1686-1701 (1984)	
	C15	Kawakami, Yutaka et al, "The Use of Melanosomal Proteins in the Immunotherapy of Melanoma," <i>Journal of Immunotherapy</i> , Vol. 21(4):237-246 (1998)	
	C16	Kobayashi, Hiroyuki et al, "Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody," <i>Protein Engineering</i> , Vol. 12(10):879-884 (1999)	
	C17	Liu, Margaret A. et al, "Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 82:8648-8652 (1985)	
	C18	Lonberg, Nils et al, "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," <i>Nature</i> , Vol. 368:856-859 (1994)	
	C19	Monteiro, Renato C. et al, "Molecular Heterogeneity of Fc α Receptors Detected by Receptor-Specific Monoclonal Antibodies," <i>The Journal of Immunology</i> , Vol. 148(6):1764-1770 (1992)	
	C20	Noorman, Femke et al, "Monoclonal antibodies against the human mannose receptor as a specific marker in flow cytometry and immunohistochemistry for macrophages," <i>Journal of Leukocyte Biology</i> , Vol. 61:63-72 (1997)	
	C21	Nouri-Shirazi, Mahyar et al, "Dendritic Cells Capture Killed Tumor Cells and Present Their Antigens to Elicit Tumor-Specific Immune Response," <i>The Journal of Immunology</i> , Vol. 165:3797-3803 (2000)	
	C22	Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies," <i>Behring Inst. Mitt.</i> , Vol. 78:118-132 (1985)	
	C23	Potter, Kathleen N. et al, "Evidence for Involvement of a Hydrophobic Patch in Framework Region 1 of Human V4-34-Encoded Ig κ s in Recognition of the Red Blood Cell I Antigen," <i>The Journal of Immunology</i> , Vol. 169:3777-3782 (2002)	
	C24	Ramakrishna, Venky et al, "Mannose Receptor Targeting of Tumor Antigen pmel17 to Human Dendritic Cells Directs Anti-Melanoma T Cell Responses via Multiple HLA Molecules," <i>The Journal of Immunology</i> , Vol. 172:2845-2852 (2004)	
	C25	Ramakrishna, Venky et al, "Synergistic Role of TLR Agonists in T Cell-Mediated Immunity Induced by Mannose Receptor Antibody Targeting of Tumor Antigens to Human DCs," <i>J. Immunother.</i> , Vol. 28(6):658 (2005)	
	C26	Sallusto, Federica et al, "Dendritic Cells Use Macropinocytosis and the Mannose Receptor to Concentrate Macromolecules in the Major Histocompatibility Complex Class II Compartment: Downregulation by Cytokines and Bacterial Products," <i>J. Exp. Med.</i> , Vol. 182:389-400 (1995)	
	C27	Tempest, Philip R. et al, "A Humanized Anti-Tumor Necrosis Factor- α Monoclonal Antibody That Acts as a Partial, Competitive Antagonist of the Template Antibody," <i>Hybridoma</i> , Vol. 13(3):183-190 (1994)	
	C28	Tjoa, Benjamin A. et al, "Development of dendritic-cell based prostate cancer vaccine," <i>Immunology Letters</i> , Vol. 74:87-93 (2000)	
	C29	Tüting, Thomas et al, "Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-Biasing Cytokines IL-12 and IFN- α ," <i>The Journal of Immunotherapy</i> , Vol. 160:1139-1147 (1998)	
↓	C30	Wallace, Paul K. et al, "Exogenous antigen targeted to Fc γ RI on Myeloid cells is presented in association with MHC class I," <i>Journal of Immunological Methods</i> , Vol. 248:183-194 (2001)	
/Y.K./	C31	Wang, Hui et al, "Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization," <i>PNAS</i> , Vol. 96(2):847-852 (2000)	

Examiner Signature		Date Considered	7/16/07
--------------------	---	-----------------	---------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/769,144-Conf. #9318
<i>(Use as many sheets as necessary)</i>				Filing Date	January 30, 2004
				First Named Inventor	Tibor KELER
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	CDJ-301

/Y.K.	C32	Ward, E. Sally et al, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , Vol. 341:544-546 (1989)	
/Y.K.	C33	You, Zhaoyang et al, "Targeting Dendritic Cells to Enhance DNA Vaccine Potency," <i>Cancer Research</i> , Vol. 61:3704-3711 (2001)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Yunsoo Kim/	Date Considered	07/16/2007
--------------------	--------------	-----------------	------------